ScandiDos AB Reports First‑Quarter 2025/26 Results
ScandiDos AB, a Swedish health‑care equipment and supplies company listed on the Stockholm Stock Exchange, published its financial results for the quarter ending 31 July 2025. The company, which develops measurement systems and software for radiation therapy in oncology, reported the following key figures:
- Net revenue: 11.5 million SEK (down from 12.6 million SEK in the same quarter last year).
- Gross margin: 75 % (slightly below 77 % in the comparable period last year).
- EBITDA: –1.6 million SEK (previously 0.2 million SEK).
- Period result: –2.2 million SEK (previously –0.6 million SEK).
The management highlighted that cost control remained effective and that pandemic‑related payment issues were decreasing. CEO Gustaf Piehl emphasized the company’s ambition to drive innovation and growth beyond stable profitability, aiming to improve the quality of future cancer treatment.
Share Performance
On the Stockholm Stock Exchange, ScandiDos shares touched a new 52‑week low of 1.15 SEK on 18 September 2025, slightly below the previous low of 1.16 SEK recorded on 29 April 2025. The share price on 16 September 2025 closed at 1.32 SEK, with a 52‑week high of 1.83 SEK reached on 8 October 2024. The company’s market capitalisation is approximately 75 million SEK.
Outlook
ScandiDos maintains a focus on patient‑quality‑assurance solutions in radiotherapy, continuing to expand its product portfolio. While the first quarter of the current fiscal year saw a decline in revenue and a negative EBITDA, the company’s management remains committed to sustaining cost discipline and pursuing growth opportunities in the oncology equipment sector.